CR9663A - Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen - Google Patents

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Info

Publication number
CR9663A
CR9663A CR9663A CR9663A CR9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A
Authority
CR
Costa Rica
Prior art keywords
processes
condensed
compositions containing
dihydropiridine
heterocicles
Prior art date
Application number
CR9663A
Other languages
English (en)
Inventor
Jacques Mauger
Anil Nair
Nina Ma
Kirsten Bjergarde
Bruno Filoche-Romme
Odile Angouillant-Boniface
Serge Mignani
Cecile Combeau
Jean-Christophe Carry
Francois Clerc
Herve Minoux
Laurent Schio
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CR9663A publication Critical patent/CR9663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. La invencion se refiere a heterociclos dihidropiridina-condensados sustituidos utiles para el tratamiento de enfermedad de cancer, especialmente para prevenir la division de celulas cancerigenas. Estos compuestos actuan como inhibidores de Aurora A y /o B quinasas.
CR9663A 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen CR9663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (en) 2005-07-20 2005-07-20 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Publications (1)

Publication Number Publication Date
CR9663A true CR9663A (es) 2008-02-21

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9663A CR9663A (es) 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Country Status (37)

Country Link
US (1) US8163768B2 (es)
EP (2) EP1746097B1 (es)
JP (2) JP2009501778A (es)
KR (1) KR101286796B1 (es)
CN (1) CN101243087B (es)
AR (1) AR054845A1 (es)
AT (2) ATE455115T1 (es)
AU (1) AU2006273692B8 (es)
BR (1) BRPI0614002A2 (es)
CA (1) CA2615700C (es)
CR (1) CR9663A (es)
CY (1) CY1109964T1 (es)
DE (1) DE602005018911D1 (es)
DK (1) DK1746097T3 (es)
DO (1) DOP2006000175A (es)
EA (1) EA016815B1 (es)
EC (1) ECSP078062A (es)
ES (1) ES2339676T3 (es)
HN (1) HN2008000088A (es)
HR (1) HRP20100195T1 (es)
IL (1) IL188861A0 (es)
MA (1) MA29634B1 (es)
MX (1) MX2008000902A (es)
MY (1) MY148617A (es)
NO (1) NO20080831L (es)
NZ (1) NZ592766A (es)
PE (2) PE20100718A1 (es)
PL (1) PL1746097T3 (es)
PT (1) PT1746097E (es)
RS (1) RS51351B (es)
SI (1) SI1746097T1 (es)
TN (1) TNSN08020A1 (es)
TW (1) TWI386411B (es)
UA (1) UA98928C2 (es)
UY (1) UY29685A1 (es)
WO (1) WO2007012972A2 (es)
ZA (1) ZA200800542B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
CA2870339C (en) 2012-05-15 2020-06-02 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PE20161416A1 (es) 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
EP3230279A1 (en) 2014-12-10 2017-10-18 Massachusetts Institute of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
WO2017124087A1 (en) 2016-01-15 2017-07-20 Memorial Sloan-Kettering Cancer Center Anti-parasitic compounds and uses thereof
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
CA3058198A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
US11084781B2 (en) 2017-05-12 2021-08-10 Research Triangle Institute Diarylureas as CB1 allosteric modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747705C (en) * 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
MXPA02005016A (es) 1999-11-19 2003-01-28 Abbott Lab Abridores de canal de potasio de dihidropirimidina triciclica.
DE60103615T2 (de) 2000-03-03 2005-06-09 Abbott Laboratories, Abbott Park Tricyclische dihydropyrazolone und tricyclische dihydroisoaxazolone als kaliumkanalöffner
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
CA2437215A1 (en) 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
FR2823854A1 (fr) * 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Also Published As

Publication number Publication date
BRPI0614002A2 (pt) 2011-03-01
MA29634B1 (fr) 2008-07-01
PT1746097E (pt) 2010-04-15
DK1746097T3 (da) 2010-05-25
PE20100718A1 (es) 2010-10-20
JP2009501778A (ja) 2009-01-22
AU2006273692B8 (en) 2012-12-13
RS51351B (sr) 2011-02-28
CY1109964T1 (el) 2014-09-10
CA2615700C (en) 2013-06-18
ZA200800542B (en) 2010-02-24
UY29685A1 (es) 2007-02-28
ES2339676T3 (es) 2010-05-24
HRP20100195T1 (hr) 2010-05-31
US8163768B2 (en) 2012-04-24
UA98928C2 (ru) 2012-07-10
WO2007012972A2 (en) 2007-02-01
AR054845A1 (es) 2007-07-18
EP1910366B1 (en) 2011-08-24
EP1746097B1 (en) 2010-01-13
EP1910366A2 (en) 2008-04-16
MY148617A (en) 2013-05-15
EA016815B1 (ru) 2012-07-30
CA2615700A1 (en) 2007-02-01
CN101243087B (zh) 2013-07-24
CN101243087A (zh) 2008-08-13
PE20070212A1 (es) 2007-03-21
AU2006273692B2 (en) 2012-11-22
DOP2006000175A (es) 2007-03-31
EP1746097A1 (en) 2007-01-24
KR20080026658A (ko) 2008-03-25
PL1746097T3 (pl) 2010-06-30
NZ592766A (en) 2012-12-21
WO2007012972A3 (en) 2007-04-05
JP2013063987A (ja) 2013-04-11
DE602005018911D1 (de) 2010-03-04
AU2006273692A1 (en) 2007-02-01
US20080261969A1 (en) 2008-10-23
IL188861A0 (en) 2008-04-13
ATE455115T1 (de) 2010-01-15
SI1746097T1 (sl) 2010-05-31
TNSN08020A1 (en) 2009-07-14
TWI386411B (zh) 2013-02-21
HN2008000088A (es) 2011-05-31
TW200740812A (en) 2007-11-01
NO20080831L (no) 2008-04-03
KR101286796B1 (ko) 2013-07-17
EA200800374A1 (ru) 2008-08-29
AU2006273692A8 (en) 2012-12-13
ATE521611T1 (de) 2011-09-15
ECSP078062A (es) 2008-01-23
MX2008000902A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
UY30748A1 (es) Compuesto0s novedosos
GT200900027A (es) Compuestos organicos
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ATE479687T1 (de) Kinaseinhibitoren
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
GT201000061A (es) Derivados de uracilo o timina para el tratamiento de hepatitis c
CR9786A (es) Compuestos de bencimidazol-tiofeno
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
GT200700006A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY29794A1 (es) Compuestos de sulfonamida, procesos e intermediarios para su preparación, composiciones farmacéuticas que los contienen y aplicaciones